JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.
Dylann Cohn-Emery
Advertisement
Articles by Dylann Cohn-Emery
Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.
Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.
The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.
Advertisement
Latest Updated Articles
Quizartinib Plus Induction Chemotherapy Provides Survival Benefit in FLT3 ITD–Mutated AMLPublished: September 8th 2023 | Updated:
BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid TumorsPublished: June 4th 2022 | Updated:
CTC Count Possible Biomarker for Using HER2-Directed Therapy in MBCPublished: December 10th 2020 | Updated:
Phase 3 Trial Set to Evaluate Venetoclax Plus Acalabrutinib or Obinutuzumab in Treatment-Naive CLL/SLLPublished: December 12th 2021 | Updated:
Encouraging Efficacy Shown With Luspatercept in MDS/MPN-RS-TPublished: December 7th 2020 | Updated:
Cilta-Cel Improves HRQoL in Relapsed/Refractory Multiple MyelomaPublished: December 6th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5